Fig. 6: AHR agonists rescue TGF-β1 impaired alveolar type 1 spheroid formation while AHR antagonists do not. | Communications Biology

Fig. 6: AHR agonists rescue TGF-β1 impaired alveolar type 1 spheroid formation while AHR antagonists do not.

From: Triggering AHR resolves TGF-β1 induced fibroblast activation and promotes AT1 cell regeneration in alveolar organoids

Fig. 6: AHR agonists rescue TGF-β1 impaired alveolar type 1 spheroid formation while AHR antagonists do not.

A Correlation between Ahr expression and AHR pathway activity across mesenchymal cell clusters from day 1, day 3, and day 11 samples separated by compound treatment. Y-axis indicates average expression of AHR pathway genes relative to random background genes in log scale. B Chemical structure of AHR agonists and antagonists. C Quantification of concentration-response curve for AHR agonists and antagonists on normalized luciferase luminescence in AHR responsive reporter assay. TE-33-UQ34 EC50 = 21 nM, R2 = 0.90. EB-06-KR05 EC50 = 6.7 nM, R2 = 0.79. QB-43-PX71 EC50 = 60 nM, R2 = 0.93. GD-70-TQ68 EC50 = 89 nM, R2 = 0.98. DC-78-LZ94 EC50 = 101 nM, R2 = 0.90. Individual data points plotted. D Quantification of concentration-response curve for AHR agonists and antagonists on GFP adjusted count spheroids in murine alveolosphere Hopx-GFP+ spheroid assay. TE-33-UQ34 EC50 = 70.2 nM, R2 = 0.77. EB-06-KR05 EC50 = 196 nM, R2 = 0.21. QB-43-PX71 EC50 = 2.1 μM, R2 = 0.59. GD-70-TQ68 EC50 = 16.2 μM, R2 = 0.29. DC-78-LZ94 EC50 = 2.5 μM, R2 = 0.51. n = 2 for all concentration except untreated well, n = 48 for untreated wells. Some untreated wells are replicated between compound curves. Individual data points plotted.

Back to article page